What are the target prices for aeglea Biotherapeutics'stock?
4 brokerages have issued twelve-month target prices for Aeglea BioTherapeutics' stock. Their forecasts range from $9.00 to $20.00. On average, they anticipate Aeglea BioTherapeutics' stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 309.2% from the stock's current price.
How do aeglea Biotherapeutics employees rate CEO Anthony Quinn on Glassdoor?
3 employees have rated Aeglea BioTherapeutics CEO Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among Aeglea BioTherapeutics' employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
Where can I buy shares of Agle?
Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What happened with the Agle IPO?
(AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.
Should I buy or sell Aeglea BioTherapeutics stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 3 hold rating...
What is Aeglea BioTherapeutics' stock price forecast for 2022?
5 brokerages have issued 1 year price objectives for Aeglea BioTherapeutics' shares. Their forecasts range from $1.00 to $20.00. On average, they e...
How has Aeglea BioTherapeutics' stock performed in 2022?
Aeglea BioTherapeutics' stock was trading at $4.75 at the beginning of 2022. Since then, AGLE shares have decreased by 85.0% and is now trading at...
When is Aeglea BioTherapeutics' next earnings date?
Aeglea BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast f...
How were Aeglea BioTherapeutics' earnings last quarter?
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) released its quarterly earnings data on Thursday, May, 5th. The biotechnology company reported ($0.37) E...
Who are Aeglea BioTherapeutics' key executives?
Aeglea BioTherapeutics' management team includes the following people: Dr. Anthony G. Quinn FRCP , M.B Ch.B., M.D., Ph.D., Pres, CEO & Director...
What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?
3 employees have rated Aeglea BioTherapeutics CEO Anthony Quinn on Glassdoor.com . Anthony Quinn has an approval rating of 100% among Aeglea BioTh...
Who are some of Aeglea BioTherapeutics' key competitors?
Some companies that are related to Aeglea BioTherapeutics include Atossa Therapeutics (ATOS) , AVEO Pharmaceuticals (AVEO) , Assertio (ASRT) ,...
What other stocks do shareholders of Aeglea BioTherapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN)...
3.5 Analyst's Opinion
Is Aeglea BioTherapeutics a buy right now?
Aeglea BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
How has Aeglea BioTherapeutics' stock been impacted by COVID-19?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aeglea BioTherapeutics stock. View analyst ratings for Aeglea BioTherapeutics or view top-rated stocks.
When is Aeglea BioTherapeutics' next earnings date?
Aeglea BioTherapeutics' stock was trading at $5.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGLE shares have decreased by 37.9% and is now trading at $3.34. View which stocks have been most impacted by COVID-19.
How were Aeglea BioTherapeutics' earnings last quarter?
Aeglea BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022. View our earnings forecast for Aeglea BioTherapeutics.
What price target have analysts set for AGLE?
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.03.
What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?
4 brokerages have issued twelve-month target prices for Aeglea BioTherapeutics' stock. Their forecasts range from $9.00 to $20.00. On average, they anticipate Aeglea BioTherapeutics' stock price to reach $13.67 in the next twelve months.
